Harpreet S. Bajaj - Concepedia

Author

Harpreet S. Bajaj

LMC Diabetes & Endocrinology (Canada)ORCID

Also Known As

Bajaj, Harpreet S., H Bajaj, H. Bajaj, H.S. Bajaj, HARPREET S. BAJAJ, HARPREET SINGH BAJAJ, Harpreet Bajaj, Harpreet S Bajaj, Harpreet S. Bajaj, Harpreet Singh Bajaj

204

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

LMC Diabetes & Endocrinology (Canada)Mount Sinai Hospital University of Toronto The University of Texas Southwestern Medical Center Novo Nordisk (Denmark)

About

Harpreet S. Bajaj is an author at LMC Diabetes & Endocrinology (Canada) specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	26	5.8K
2	Diabetes	18	24	5.6K
3	Public Health	6	6	3K
4	Health Sciences	4	4	274
5	Biochemistry	1	1	51

Harpreet S. Bajaj

Publications

7.8K

Citations

H-Index

Page 1

	Year	Citations
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes	2019	600
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress, The Lancet UrologyRenal DiseaseRenal EventsRenal FunctionDiabetes	2019	589
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Stefano Del Prato, Steven E. Kahn, Imre Pávó, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseMedicineInsulin Management	2021	586
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment Julio Rosenstock, Harpreet S. Bajaj, Andrej Janež, New England Journal of Medicine	2020	201
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial Meg Jardine, Zien Zhou, Kenneth W. Mahaffey, Journal of the American Society of Nephrology	2020	172
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial Juan P. Frías, Pernille Auerbach, Harpreet S. Bajaj, The Lancet Diabetes & Endocrinology Diabetes ManagementOnce-weekly Semaglutide 2·0MedicineDiabetesClinical Trials	2021	155
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, The Lancet HypertensionRenal FunctionRenal DiseaseMedicineKidney Failure	2023	151
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S. Bajaj, The Lancet Diabetes ManagementInsulin ManagementDiabetesClinical TrialsOnce-weekly Insulin	2023	130
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial Harpreet S. Bajaj, Richard M. Bergenstal, Andreas Christoffersen, Diabetes Care	2021	120

Page 1